Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Profectus BioSciences
Vaccines
CEPI awards IDT Biologika up to $36M for MERS research
Right on the heels of last week's deal in Lassa fever, CEPI has awarded IDT Biologika up to $36 million for MERS research.
Eric Sagonowsky
Aug 21, 2018 11:10am
Profectus, Emergent win $36M deal for Lassa vaccine
Aug 20, 2018 12:20pm
WHO reports Ebola outbreak has 'largely been contained'
Jun 27, 2018 8:45am
Profectus, Emergent to work on Nipah vaccine under $25M CEPI deal
May 25, 2018 10:50am
GSK's Mosquirix, Emergent BioSolutions and more—News of Note
Apr 18, 2018 9:57am